SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(de Mestier Louis)
 

Sökning: WFRF:(de Mestier Louis) > Carvhalo Luciana > Value of Tumor Grow...

  • Lamarca, AngelaDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom (författare)

Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET) : The GREPONET Study

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019-03-25
  • Oxford University Press (OUP),2019
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-382950
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-382950URI
  • https://doi.org/10.1634/theoncologist.2018-0672DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • INTRODUCTION: Tumor growth rate (TGR; percent size change per month [%/m]) is postulated to be an early radiological biomarker to overcome limitations of RECIST. This study aimed to assess the impact of TGR in neuroendocrine tumors (NETs) and potential clinical and therapeutic applications.MATERIALS AND METHODS: Patients (pts) with advanced grade (G) 1/2 NETs from the pancreas or small bowel initiating systemic treatment (ST) or watch and wait (WW) were eligible. Baseline and follow-up scans were retrospectively reviewed to calculate TGR at pretreatment (TGR0), first follow-up (TGRfirst), and 3(±1) months of study entry (TGR3m).RESULTS: Out of 905 pts screened, 222 were eligible. Best TGRfirst (222 pts) cutoff was 0.8 (area under the curve, 0.74). When applied to TGR3m (103 pts), pts with TGR3m <0.8 (66.9%) versus TGR3m ≥ 0.8 (33.1%) had longer median progression-free survival (PFS; 26.3 m; 95% confidence interval [CI] 19.5-32.4 vs. 9.3 m; 95% CI, 6.1-22.9) and lower progression rate at 12 months (7.3% vs. 56.8%; p = .001). WW (vs. ST) and TGR3m ≥ 0.8 (hazard ratio [HR], 3.75; 95% CI, 2.21-6.34; p < .001) were retained as factors associated with a shorter PFS in multivariable Cox regression. TGR3m (HR, 3.62; 95% CI, 1.97-6.64; p < .001) was also an independent factor related to shorter PFS when analysis was limited to pts with stable disease (81 pts). Out of the 60 pts with TGR0 data available, 60% of pts had TGR0 < 4%/month. TGR0 ≥ 4 %/month (HR, 2.22; 95% CI, 1.15-4.31; p = .018) was also an independent factor related to shorter PFS.CONCLUSION: TGR is an early radiological biomarker able to predict PFS and to identify patients with advanced NETs who may require closer radiological follow-up.IMPLICATIONS FOR PRACTICE: Tumor growth rate at 3 months (TGR3m) is an early radiological biomarker able to predict progression-free survival and to identify patients with advanced neuroendocrine tumors who may require closer radiological follow-up. It is feasible to calculate TGR3m in clinical practice and it could be a useful tool for guiding patient management. This biomarker could also be implemented in future clinical trials to assess response to therapy.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Crona, JoakimUppsala universitet,Endokrinkirurgi,Endokrin tumörbiologi(Swepub:uu)joacr310 (författare)
  • Ronot, MaximeDepartment of Radiology, Beaujon University Hospital, Clichy, France (författare)
  • Opalinska, MartaNuclear Medicine Unit, Department of Endocrinology, University Hospital, Krakow, Poland (författare)
  • Lopez Lopez, CarlosDepartment of Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain (författare)
  • Pezzutti, DanielaDepartment of Radiology, Israelita Albert Einstein Hospital, Sao Paulo, Brazil (författare)
  • Najran, PavanDepartment of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom (författare)
  • Carvhalo, LucianaDepartment of Medical Oncology, Sirio‐Libanes Hospital, Sao Paulo, Brazil (författare)
  • Franca Bezerra, Regis OtavianoDepartment of Radiology, Sirio‐Libanes Hospital, Sao Paulo, Brazil ; São Paulo Cancer Institute Octavio Frias de Oliveira, Sao Paulo, Brazil (författare)
  • Borg, PhilipDepartment of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom (författare)
  • Vietti Violi, NaikDepartment of Radiology, CHUV University Hospital, Lausanne, Switzerland (författare)
  • Vidal Trueba, HectorDepartment of Radiology, Hospital Universitario Marques de Valdecilla, Santander, Spain (författare)
  • de Mestier, LouisDepartment of Gastroenterology, Beaujon University Hospital, Clichy, France (författare)
  • Schaefer, NiklausDepartment of Medical Oncology, CHUV University Hospital, Lausanne, Switzerland (författare)
  • Sundin, Anders,1954-Uppsala universitet,Radiologi(Swepub:uu)anderssu (författare)
  • Costa, FredericoDepartment of Medical Oncology, Sirio‐Libanes Hospital, Sao Paulo, Brazil (författare)
  • Pavel, MarianneDepartment of Medicine 1, Division of Endocrinology, Friedrich‐Alexander University Erlangen‐Nürnberg, Erlangen, Germany (författare)
  • Dromain, ClarisseDepartment of Radiology, CHUV University Hospital, Lausanne, Switzerland (författare)
  • Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United KingdomEndokrinkirurgi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:The Oncologist: Oxford University Press (OUP)24:11, s. E1082-E10901083-71591549-490X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy